Lifeward Ltd. reports developments for a medical technology company focused on physical rehabilitation and recovery. Its product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity System, MyoCycle FES System, and ReStore Exo-Suit, with use in clinical settings and in home or community rehabilitation.
Company news covers financial results, access initiatives for the FDA-cleared ReWalk Personal Exoskeleton, collaborations with rehabilitation providers, and regulatory or clinical disclosures tied to rehabilitation technologies. Other recurring updates address Nasdaq listing compliance, shareholder voting matters, governance changes, material agreements, acquisitions, and capital-structure actions involving ordinary shares and warrants.
Lifeward (LFWD) reported a peer-reviewed, independent pilot study of its ReWalk personal exoskeleton in 12 individuals with paraplegia due to chronic spinal cord injury, showing statistically significant improvements in daily activity performance, satisfaction and pain versus wheelchair use.
All participants completed kitchen tasks and 10 completed grooming tasks while standing at home in the exoskeleton. COPM performance scores (P=.008) and satisfaction scores (P=.003) improved, RNLI-M scores increased (P=.04), and pain scores were lower versus wheelchair use on the NPRS (P=.01). Eight of 12 participants reported improved bowel and bladder function. The publication coincides with expanding commercial access: ReWalk sales rose 13% year-over-year to $2.5 million in Q2 2026, contributing to a 16% increase in total Lifeward revenue to $6.6 million, alongside growing Medicare and Medicare Advantage coverage and a new U.S. distribution pilot with Ottobock Care.
Lifeward (LFWD) released an updated investor presentation outlining its commercial growth strategy and business priorities.
The presentation, available on the company’s investor relations website, reviews plans to scale its established rehabilitation platform, leverage existing reimbursement infrastructure, and expand a capital-efficient distribution network. It also showcases recent commercial performance, updates on the product development pipeline, and details of Lifeward’s strategic partnership with Oramed Pharmaceuticals.
Lifeward (Nasdaq: LFWD) appointed Josh Hexter as Interim Chief Executive Officer effective September 1, 2026 and Rami Aviram as Chief Financial Officer effective November 1, 2026. Hexter succeeds Mark Grant, who is leaving to pursue other opportunities and will consult through September 30, 2026 to support a smooth transition.
According to Lifeward, the company enters this leadership change with growing commercial momentum. In the second quarter of 2026, revenue rose 16% year-over-year to $6.6 million, its strongest quarterly revenue since Q4 2024. ReWalk Personal Exoskeleton sales increased 13%, while AlterG product and service revenue grew 25%, reflecting progress in scaling its rehabilitation business.
Hexter brings nearly three decades of life sciences leadership, including senior roles at Oramed Pharmaceuticals and BrainsWay, while Aviram has led finance functions at technology and medical device companies such as Beewise and ENDYMED Medical.
Nano Dimension (Nasdaq: NNDM) appointed Nadav Kidron to its Board of Directors and plans to form a new Strategy and Capital Allocation Committee as part of an ongoing strategic review led by Chairman Phillip Borenstein.
Kidron, President and CEO of Oramed Pharmaceuticals (Nasdaq: ORMP) and a director at Alpha Tau Medical (Nasdaq: DRTS) and Lifeward (Nasdaq: LFWD), will chair the committee. According to Nano Dimension, the committee will help evaluate capital allocation alternatives, potential returns of excess capital to shareholders, monetization of non-core assets and other strategic opportunities aimed at maximizing long-term shareholder value.
Lifeward (Nasdaq: LFWD) reported second quarter 2026 revenue of $6.6 million, up 16% year over year, its strongest quarter since Q4 2024. Growth was led by a 13% increase in ReWalk Personal exoskeleton sales to $2.5 million and a 25% rise in AlterG products and services to $4.1 million. Gross margin was 41%, down from 44% a year earlier.
Total operating expenses fell 24% to $6.9 million, reducing GAAP operating loss by 37% to $4.2 million. GAAP net loss widened to $11.5 million, mainly from non-cash fair value charges, while non-GAAP net loss was $4.1 million. Cash and equivalents rose to $9.4 million from $2.2 million at year-end 2025, with pro forma cash of about $11 million including July financing. Lifeward highlighted a distribution pilot with Ottobock Care, progress toward a U.S. Phase 2 trial of ORMD-0801 oral insulin, and announced board departures and the planned September 30, 2026 exit of its CFO.
Lifeward (Nasdaq: LFWD) announced it will report its second quarter 2026 financial results on Friday, August 14, 2026. According to the company, a press release and the quarterly report will be made available and filed with the SEC before 9:30 a.m. ET. Lifeward also stated it will not hold a conference call in connection with this earnings release.
Lifeward (Nasdaq: LFWD) launched a six-month pilot program with Ottobock Care, a leading U.S. orthotics and prosthetics patient care organization, to expand access to the ReWalk® 7 Personal Exoskeleton.
The collaboration combines Lifeward’s neurorehabilitation exoskeleton technology with Ottobock Care’s network of more than 50 clinics, clinical expertise and patient support teams. The pilot aims to increase awareness of ReWalk 7 at rehabilitation hospitals and spinal cord injury centers, develop regional clinical and reimbursement expertise, and create sustainable local support for evaluation, training and follow-up, with the goal of establishing a scalable model for potential broader U.S. distribution.
Lifeward (Nasdaq: LFWD) arranged up to $11.2 million in strategic financing through senior secured convertible notes and warrants. An initial $5.6 million closed on July 6, 2026, with another $5.6 million contingent on specific commercial and share-price milestones.
This deal expands access to capital under a broader Oramed-linked framework of up to $47 million, of which $10 million was previously funded, supporting commercialization of Lifeward’s neurorehabilitation platform.
Oramed (NASDAQ: ORMP) released a shareholder letter detailing portfolio gains, Scilex loan repayments, and upcoming Russell 2000/3000 index inclusion.
Key points include Alpha Tau's value rising to about $167M, Scilex repayments totaling roughly $118M to date, and total cash and assets of about $270M as of March 31, 2026 (unaudited).
Lifeward (Nasdaq: LFWD) appointed Dr. Keith D. Rose as Chief Medical Officer, effective May 19, 2026, to lead its global medical strategy.
Dr. Rose brings 30 years of rehabilitation and neuroscience experience and will support expansion of Lifeward’s neurorehabilitation portfolio and newly acquired biomedical assets.